Anika Therapeutics
ANIK
Anika Therapeutics (ANIK) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.42
- EPS estimate
- −$0.08
- EPS surprise
- +625.00%
- Revenue surprise
- +11.62%
- Revenue
- $32.6M
- Revenue estimate
- $29.2M
- Reported
- Jul 29, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 29, 2026 | −$0.08 | $0.42 | +625.00% | $32.6M | SEC |
| Q1 2026 | Apr 29, 2026 | −$0.07 | $0.27 | +485.71% | $29.6M | SEC |
| Q4 2025 | Feb 26, 2026 | −$0.13 | $0.31 | +348.00% | $30.6M | SEC |
| Q3 2025 | Nov 5, 2025 | −$0.18 | $0.04 | +122.22% | $27.8M | SEC |
| Q2 2025 | Jul 30, 2025 | −$0.26 | −$0.13 | +50.63% | $28.2M | SEC |
| Q1 2025 | May 9, 2025 | −$0.09 | −$0.06 | +33.33% | $26.2M | SEC |
| Q4 2024 | Mar 12, 2025 | −$0.23 | −$0.03 | +86.67% | $30.6M | SEC |
| Q3 2024 | Oct 31, 2024 | $0.09 | −$0.25 | −377.78% | $38.8M | SEC |
| Q2 2024 | Aug 8, 2024 | $0.07 | $0.17 | +154.87% | $41.9M | SEC |
| Q1 2024 | May 8, 2024 | −$0.08 | $0.09 | +212.50% | $40.5M | SEC |
| Q4 2023 | Mar 13, 2024 | −$0.23 | $0.05 | +122.06% | $43.0M | SEC |
| Q3 2023 | Nov 2, 2023 | −$0.35 | $0.00 | +100.00% | $41.5M | SEC |
| Q2 2023 | Aug 8, 2023 | −$0.32 | $0.06 | +118.75% | $44.3M | SEC |
| Q1 2023 | May 9, 2023 | −$0.34 | −$0.36 | −5.88% | $37.9M | SEC |
| Q4 2022 | Mar 6, 2023 | −$0.24 | −$0.34 | −41.67% | $39.6M | SEC |
| Q3 2022 | Nov 8, 2022 | −$0.25 | −$0.29 | −16.00% | $40.3M | — |
| Q2 2022 | Aug 3, 2022 | −$0.23 | −$0.20 | +11.78% | $39.7M | — |
| Q1 2022 | May 5, 2022 | −$0.33 | −$0.20 | +39.99% | $36.7M | — |
| Q4 2021 | Mar 8, 2022 | −$0.28 | −$0.40 | −41.19% | $35.8M | — |
| Q3 2021 | Nov 4, 2021 | −$0.21 | $0.04 | +119.03% | $39.5M | — |
Quarterly revenue
Frequently asked questions
When did Anika Therapeutics (ANIK) last report earnings?
Anika Therapeutics last reported on Jul 29, 2026, covering fiscal Q2 2026.
Did ANIK beat earnings estimates?
Yes. Anika Therapeutics reported EPS of $0.42 for Q2 2026 against a −$0.08 estimate — a 625.00% beat.
How much revenue did ANIK report last quarter?
Anika Therapeutics reported $32.6M in revenue for Q2 2026, against a consensus estimate of $29.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.